(Q47782716)

5 February 2018

title

Measurement of chemoresistance markers in patients with stage III non-small cell lung cancer: a novel approach for patient selection. (English)

1 reference

5 February 2018

author name string

Kelli R Brooks

1

1 reference

5 February 2018

Kathleen To

2

1 reference

5 February 2018

Mary-Beth Moore Joshi

3

1 reference

5 February 2018

Debbi H Conlon

4

1 reference

5 February 2018

James E Herndon

5

1 reference

5 February 2018

Thomas A D'Amico

6

1 reference

5 February 2018

David H Harpole

7

1 reference

5 February 2018

language of work or name

English

0 references

publication date

1 July 2003

1 reference

5 February 2018

The Annals of Thoracic Surgery

published in

1 reference

5 February 2018

volume

76

1 reference

5 February 2018

issue

1

1 reference

5 February 2018

page(s)

187-93; discussion 193

1 reference

5 February 2018

cites work

Cancer statistics, 1998.

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2803%2900131-0

Vinflunine (20',20'-difluoro-3',4'-dihydrovinorelbine), a novel Vinca alkaloid, which participates in P-glycoprotein (Pgp)-mediated multidrug resistance in vivo and in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2803%2900131-0

P-glycoprotein mediated resistance to 5'-nor-anhydro-vinblastine (Navelbine)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2803%2900131-0

Vinorelbine (Navelbine): a third-generation vinca alkaloid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2803%2900131-0

DNA mismatch repair deficient mice in cancer research

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2803%2900131-0

Cisplatin resistance and DNA repair

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2803%2900131-0

hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2803%2900131-0

A biologic risk model for stage I lung cancer: immunohistochemical analysis of 408 patients with the use of ten molecular markers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2803%2900131-0

Tumor marker expression is predictive of survival in patients with esophageal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2803%2900131-0

The interactive effect of Ras, HER2, P53 and Bcl-2 expression in predicting the survival of non-small cell lung cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2803%2900131-0

Vinorelbine: a novel vinca alkaloid.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2803%2900131-0

Immunohistochemically detected p53 and P-glycoprotein predict the response to chemotherapy in lung cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2803%2900131-0

Expression of p53 and glutathione S-transferase-pi relates to clinical drug resistance in non-small cell lung cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2803%2900131-0

Disruption of p53 in human cancer cells alters the responses to therapeutic agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2803%2900131-0

Chemotherapy for advanced non-small cell lung cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2803%2900131-0

Molecular biologic substaging of stage I lung cancer according to gender and histology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2803%2900131-0

10.1016/S0003-4975(03)00131-0

7 January 2021

Identifiers

DOI

1 reference

5 February 2018

PubMed ID

12842538

1 reference

5 February 2018